Cancer Family
Malignant Soft Tissue Neoplasm
CI-CAN-00000251Explore in graph →
341 active trials9 approved drugs37 evidence items
- NCIt
- C4867
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000251Explore in graph →
Clinical trials
1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (200)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | terminated | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 |
| clinicaltrials |
| NCT04037527 | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities | terminated | Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | terminated | Phase 3 | 218 | Polaris GroupINDUSTRY | 3 | Jun 25, 2026 | clinicaltrials |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | terminated | Phase 3 | 107 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | terminated | Phase 2 | 8 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma | terminated | Phase 2 | 11 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04123535 | Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma(HIFU-UPS) | terminated | N/A | 5 | Matthew BucknorOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT01612481 | Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma(CASSANDRE) | terminated | Phase 2 | 11 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05116254 | Sarcomas and DDR-Inhibition; a Combined Modality Study(SADDRIN-1) | terminated | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. | terminated | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04204941 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | terminated | Phase 1 | 25 | Epizyme, Inc.INDUSTRY | 4 | Jan 7, 2026 | clinicaltrials |
| NCT06050434 | Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients(PROTraSarc) | terminated | — | 7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | HiFiBiO TherapeuticsINDUSTRY | 2 | Oct 22, 2025 | clinicaltrials |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy | terminated | Phase 2 | 110 | Washington University School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | terminated | Phase 3 | 1,272 | BayerINDUSTRY | 13 | Jul 28, 2025 | clinicaltrials |
| NCT04220229 | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | terminated | Phase 1 / Phase 2 | 6 | University of WashingtonOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | terminated | Phase 1 | 20 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 2 | Jun 25, 2025 | clinicaltrials |
| NCT04347122 | Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction | terminated | Phase 4 | 12 | University of Kansas Medical CenterOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT03660930 | Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | terminated | Phase 1 / Phase 2 | 19 | University of WashingtonOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization(PEDD-UFE) | terminated | N/A | 3 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | terminated | Phase 1 | 55 | Foghorn Therapeutics Inc.INDUSTRY | 4 | Mar 4, 2025 | clinicaltrials |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients(TOASTIT) | terminated | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05100628 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma | terminated | Phase 1 | 9 | Noxopharm LimitedINDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | terminated | Phase 1 | 49 | C4 Therapeutics, Inc.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03118037 | Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry(SAGE) | terminated | — | 182 | GynesonicsINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT05017103 | Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03116529 | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma(NEXIS) | terminated | Phase 1 / Phase 2 | 22 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors(CAR) | terminated | Phase 1 | 9 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04879979 | GIST and Memory and Attention Adaptation Training(GIST-MAAT) | terminated | N/A | 2 | University of PittsburghOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04656262 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients(METROPHOLYS) | terminated | Phase 3 | 79 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | terminated | Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03132155 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | terminated | Phase 2 | 8 | NantPharma, LLCINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | terminated | — | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05043649 | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | terminated | Phase 1 | 14 | Monopar TherapeuticsINDUSTRY | 1 | May 16, 2024 | clinicaltrials |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | terminated | Phase 1 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | terminated | Phase 1 | 29 | Pyramid BiosciencesINDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | terminated | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials